Go Pro
→ PH: Do THESE 4 things to your bank account now … (From Weiss Ratings) (Ad)tc pixel Free CSBR Stock Alerts

Champions Oncology (CSBR) Competitors

Champions Oncology logo
$5.85 +0.09 (+1.56%)
Closing price 07/6/2026 04:00 PM Eastern
Extended Trading
$5.88 +0.03 (+0.56%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CSBR vs. SLN, OABI, ORGO, SIGA, and AKBA

Should you buy Champions Oncology stock or one of its competitors? MarketBeat compares Champions Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Champions Oncology include Silence Therapeutics (SLN), OmniAb (OABI), Organogenesis (ORGO), Siga Technologies (SIGA), and Akebia Therapeutics (AKBA). These companies are all part of the "med - drugs" industry.

How does Champions Oncology compare to Silence Therapeutics?

Champions Oncology (NASDAQ:CSBR) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

Champions Oncology has a net margin of -3.94% compared to Silence Therapeutics' net margin of -8,943.86%. Champions Oncology's return on equity of -57.31% beat Silence Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Champions Oncology-3.94% -57.31% -7.51%
Silence Therapeutics -8,943.86%-105.34%-52.79%

41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 46.4% of Champions Oncology shares are held by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Champions Oncology has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

Champions Oncology has higher revenue and earnings than Silence Therapeutics. Champions Oncology is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Champions Oncology$56.94M1.43$4.70M-$0.16N/A
Silence Therapeutics$560K892.50-$88.61M-$1.59N/A

In the previous week, Silence Therapeutics had 1 more articles in the media than Champions Oncology. MarketBeat recorded 1 mentions for Silence Therapeutics and 0 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 0.00 beat Silence Therapeutics' score of -0.72 indicating that Champions Oncology is being referred to more favorably in the media.

Company Overall Sentiment
Champions Oncology Neutral
Silence Therapeutics Negative

Silence Therapeutics has a consensus price target of $55.00, suggesting a potential upside of 419.85%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than Champions Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Champions Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Silence Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.83

Summary

Silence Therapeutics beats Champions Oncology on 9 of the 17 factors compared between the two stocks.

How does Champions Oncology compare to OmniAb?

Champions Oncology (NASDAQ:CSBR) and OmniAb (NASDAQ:OABI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Champions Oncology has a net margin of -3.94% compared to OmniAb's net margin of -187.59%. OmniAb's return on equity of -20.31% beat Champions Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Champions Oncology-3.94% -57.31% -7.51%
OmniAb -187.59%-20.31%-18.10%

In the previous week, OmniAb had 1 more articles in the media than Champions Oncology. MarketBeat recorded 1 mentions for OmniAb and 0 mentions for Champions Oncology. OmniAb's average media sentiment score of 0.94 beat Champions Oncology's score of 0.00 indicating that OmniAb is being referred to more favorably in the news media.

Company Overall Sentiment
Champions Oncology Neutral
OmniAb Positive

Champions Oncology has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, OmniAb has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market.

Champions Oncology has higher revenue and earnings than OmniAb. Champions Oncology is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Champions Oncology$56.94M1.43$4.70M-$0.16N/A
OmniAb$18.67M18.69-$64.78M-$0.46N/A

41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 72.1% of OmniAb shares are owned by institutional investors. 46.4% of Champions Oncology shares are owned by company insiders. Comparatively, 9.8% of OmniAb shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

OmniAb has a consensus price target of $3.00, indicating a potential upside of 24.48%. Given OmniAb's stronger consensus rating and higher probable upside, analysts plainly believe OmniAb is more favorable than Champions Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Champions Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
OmniAb
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Summary

OmniAb beats Champions Oncology on 10 of the 16 factors compared between the two stocks.

How does Champions Oncology compare to Organogenesis?

Champions Oncology (NASDAQ:CSBR) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Organogenesis has a net margin of -0.84% compared to Champions Oncology's net margin of -3.94%. Organogenesis' return on equity of 9.63% beat Champions Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Champions Oncology-3.94% -57.31% -7.51%
Organogenesis -0.84%9.63%4.76%

41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 46.4% of Champions Oncology shares are owned by company insiders. Comparatively, 18.8% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Champions Oncology has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, Organogenesis has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market.

Organogenesis has a consensus price target of $5.75, suggesting a potential upside of 131.85%. Given Organogenesis' stronger consensus rating and higher possible upside, analysts plainly believe Organogenesis is more favorable than Champions Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Champions Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Organogenesis
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Organogenesis has higher revenue and earnings than Champions Oncology. Champions Oncology is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Champions Oncology$56.94M1.43$4.70M-$0.16N/A
Organogenesis$564.17M0.57$37.03M-$0.19N/A

In the previous week, Organogenesis had 1 more articles in the media than Champions Oncology. MarketBeat recorded 1 mentions for Organogenesis and 0 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 0.00 equaled Organogenesis'average media sentiment score.

Company Overall Sentiment
Champions Oncology Neutral
Organogenesis Neutral

Summary

Organogenesis beats Champions Oncology on 12 of the 15 factors compared between the two stocks.

How does Champions Oncology compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Siga Technologies has higher revenue and earnings than Champions Oncology. Champions Oncology is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Siga Technologies$94.57M2.84$23.28M$0.2713.89
Champions Oncology$56.94M1.43$4.70M-$0.16N/A

Siga Technologies has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Champions Oncology has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

In the previous week, Siga Technologies had 1 more articles in the media than Champions Oncology. MarketBeat recorded 1 mentions for Siga Technologies and 0 mentions for Champions Oncology. Siga Technologies' average media sentiment score of 0.14 beat Champions Oncology's score of 0.00 indicating that Siga Technologies is being referred to more favorably in the media.

Company Overall Sentiment
Siga Technologies Neutral
Champions Oncology Neutral

55.4% of Siga Technologies shares are owned by institutional investors. Comparatively, 41.3% of Champions Oncology shares are owned by institutional investors. 2.7% of Siga Technologies shares are owned by insiders. Comparatively, 46.4% of Champions Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Siga Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Champions Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Siga Technologies has a net margin of 21.58% compared to Champions Oncology's net margin of -3.94%. Siga Technologies' return on equity of 10.60% beat Champions Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Siga Technologies21.58% 10.60% 8.94%
Champions Oncology -3.94%-57.31%-7.51%

Summary

Siga Technologies beats Champions Oncology on 12 of the 13 factors compared between the two stocks.

How does Champions Oncology compare to Akebia Therapeutics?

Akebia Therapeutics (NASDAQ:AKBA) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

Champions Oncology has a net margin of -3.94% compared to Akebia Therapeutics' net margin of -8.83%. Champions Oncology's return on equity of -57.31% beat Akebia Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Akebia Therapeutics-8.83% -62.72% -5.66%
Champions Oncology -3.94%-57.31%-7.51%

Champions Oncology has lower revenue, but higher earnings than Akebia Therapeutics. Champions Oncology is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akebia Therapeutics$236.20M1.48-$5.34M-$0.08N/A
Champions Oncology$56.94M1.43$4.70M-$0.16N/A

In the previous week, Akebia Therapeutics had 8 more articles in the media than Champions Oncology. MarketBeat recorded 8 mentions for Akebia Therapeutics and 0 mentions for Champions Oncology. Akebia Therapeutics' average media sentiment score of 0.27 beat Champions Oncology's score of 0.00 indicating that Akebia Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Akebia Therapeutics Neutral
Champions Oncology Neutral

33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 41.3% of Champions Oncology shares are held by institutional investors. 4.3% of Akebia Therapeutics shares are held by company insiders. Comparatively, 46.4% of Champions Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Akebia Therapeutics has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, Champions Oncology has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market.

Akebia Therapeutics currently has a consensus price target of $4.67, indicating a potential upside of 258.97%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Akebia Therapeutics is more favorable than Champions Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akebia Therapeutics
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20
Champions Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Akebia Therapeutics beats Champions Oncology on 10 of the 16 factors compared between the two stocks.

Get Champions Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CSBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CSBR vs. The Competition

Export
MetricChampions OncologyMED IndustryMedical SectorNASDAQ Exchange
Market Cap$79.99M$3.10B$6.92B$12.59B
Dividend YieldN/A2.05%2.66%6.52%
P/E Ratio-36.5620.0527.3524.81
Price / Sales1.43383.84507.7389.92
Price / Cash12.5657.1829.6549.23
Price / Book21.674.3611.066.50
Net Income$4.70M$64.65M$3.57B$336.03M
7 Day Performance-5.03%1.26%2.56%2.68%
1 Month Performance3.54%7.16%7.39%5.50%
1 Year Performance-34.38%29.42%34.13%25.01%

Champions Oncology Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CSBR
Champions Oncology
0.1566 of 5 stars		$5.85
+1.6%		N/A-24.7%$79.99M$56.94MN/A143
SLN
Silence Therapeutics
2.4331 of 5 stars		$9.16
+26.0%		$55.00
+500.4%		+91.0%$343.40M$560KN/A100
OABI
OmniAb
2.8296 of 5 stars		$2.28
-2.1%		$3.00
+31.6%		+23.9%$337.34M$18.67MN/A7
ORGO
Organogenesis
1.797 of 5 stars		$2.44
+0.4%		$5.75
+135.7%		-43.0%$312.68M$564.17MN/A950
SIGA
Siga Technologies
0.9107 of 5 stars		$4.32
+0.5%		N/A-44.3%$308.41M$94.57M16.0040

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CSBR) was last updated on 7/7/2026 by MarketBeat.com Staff.
From Our Partners
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel